Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to Buy at StockNews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday.

Several other research firms have also commented on REGN. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. UBS Group lifted their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Finally, Truist Financial restated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $977.77.

Regeneron Pharmaceuticals Trading Up 1.1 %

Shares of REGN stock opened at $892.48 on Tuesday. The stock has a market cap of $97.96 billion, a P/E ratio of 25.68, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11. Regeneron Pharmaceuticals has a 1 year low of $684.80 and a 1 year high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The stock has a 50 day simple moving average of $946.89 and a 200 day simple moving average of $894.83.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the previous year, the firm earned $10.96 EPS. The company’s quarterly revenue was up .6% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals will post 38.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,195 shares of company stock worth $9,759,898. Insiders own 8.83% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Meyer Handelman Co. lifted its stake in Regeneron Pharmaceuticals by 11.4% in the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock valued at $3,485,000 after buying an additional 435 shares during the period. Stifel Financial Corp boosted its stake in Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after acquiring an additional 3,385 shares in the last quarter. LPL Financial LLC grew its holdings in Regeneron Pharmaceuticals by 9.3% in the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after purchasing an additional 3,479 shares during the period. Exchange Traded Concepts LLC increased its stake in Regeneron Pharmaceuticals by 32.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after purchasing an additional 1,221 shares in the last quarter. Finally, Monetary Management Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the third quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company’s stock valued at $901,000 after purchasing an additional 50 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.